

NEW APPROACHES IN THE TREATMENT OF CORONARY ARTERY DISEASE

Evolution of Coronary Artery Stents
and Scaffolding Devices

PROGRAM SYLLABUS



Rockpointe

A CME-CERTIFIED GRAND ROUNDS PROGRAM

Jointly provided by The Society for Cardiovascular Angiography and Interventions
and Rockpointe

This activity is supported through an educational grant from Abbott Vascular

CONTENTS

Program Overview/Statement of Need	Page 3
Target Audience and Learning Objectives.....	Page 3
CME Statements	Page 4
Disclosures	Page 5
Glossaries for Drug-Eluting Stents	Page 6
Steering Committee.....	Pages 7-8

ADDITIONAL PACKET CONTENTS

Participant Survey and CME Evaluation..... Front of packet

After filling out the Activity Survey, Post-activity Survey, and CME Evaluation, please separate from packet and return to onsite staff

Program Slides

A copy of the presentation slides with space for note-taking

PROGRAM OVERVIEW/STATEMENT OF NEED

The Potomac Center for Medical Education and Rockpointe welcome you to **New Approaches in the Treatment of Coronary Artery Disease: *Evolution of Coronary Artery Stents and Scaffolding Devices***, a CME-certified Grand Rounds activity designed to give medical professionals the latest news and information on the management of coronary artery disease patients.

Coronary stents have been proven to save lives during a heart attack and in patients with critical blockages that cause unstable symptoms. However, there is less certainty about angioplasty's benefits for survival and heart-attack prevention in lower-risk patients with stable coronary artery disease (CAD). There is also considerable controversy regarding the relative efficacy of percutaneous coronary intervention (PCI) vs coronary artery bypass surgery (CABG) and when to use each to manage patients.

New Approaches in the Treatment of Coronary Artery Disease will review the existing treatment options and their efficacy and safety profiles and explore when each is appropriate to use in which patients. The CME activity will also examine emerging and new innovations, such as drug-eluting stents (DES) with anti-proliferative drugs and antibodies, DES with biologically inert polymers, and fully bio-absorbable stent scaffoldings.

TARGET AUDIENCE

This activity is intended for interventional cardiologists, cardiologists, and other physicians who manage patients with CAD. This includes those specialists who provide early evaluation of acute chest pain and diagnosis of CAD, prompt referral and continuity of care on hospital admission, and long-term management of ACS patients through a pivotal role in post-discharge care.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

- Understand whether PCI is an appropriate management choice to improve clinical outcomes of patients with CAD
- Implement patient treatment strategies based on an understanding of the strengths and weaknesses of available stent and scaffolding technologies
- Analyze emerging stent and scaffolding technologies and assess how best to use these technologies to improve patient outcomes

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Society for Cardiovascular Angiography and Interventions and Rockpointe. The Society for Cardiovascular Angiography and Interventions is accredited by the ACCME to provide continuing medical education for physicians.

For information about the accreditation of this program, please email: info@SCAI.org.

PHYSICIAN CREDIT DESIGNATION

The Society for Cardiovascular Angiography and Interventions designates this live activity for a maximum of 1.0 *AMA PRA Category 1 credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SPECIAL SERVICES



Event staff will be glad to assist you with any special needs.

FEE AND RECEIVING CME CREDIT

There is no fee for this educational activity. To receive CME credit the participant must:

- Participate in this one-hour-long program in its entirety;
- Sign in on the sheet provided by the host coordinator;
- Complete the evaluation forms;
- Return the evaluation forms to the host coordinator.

DISCLOSURE/CONFLICT OF INTEREST STATEMENT

As part of The Society for Cardiovascular Angiography and Interventions' (SCAI's) ACCME compliance activities, SCAI collects disclosure information from all faculty and staff members indicating relevant financial relationships with commercial interests. Faculty disclosure information will be made known to the participants prior to the activity.

The content of this activity was vetted by SCAI Education Committee members to assure objectivity and that the activity is free of commercial bias.

DISCLOSURES

Steering Committee

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Cindy Grines, MD, FACC, FSCAI: *Consultant:* Abbott Vascular, Medicines Company, Merck, Volcano Group

James B. Hermiller, MD, FACC, FSCAI: *Consultant:* Abbott Vascular, Boston Scientific, Edwards, Medtronic; *Research:* Abbott Vascular, Boston Scientific, Edwards, Medtronic

Non-faculty Content Contributors

SCAI and Rockpointe non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

SCAI Education Committee (provided peer review for all content):

J. Dawn Abbott: *Consultant:* Pfizer; *Research:* Abbott Cardiovascular Systems, AstraZeneca, Medinol Ltd.

Robert Applegate: *Advisory Board/Consultant:* Abbott Vascular

Ehrin Armstrong: *Advisory Board:* Abbott Vascular, Boston Scientific, Medtronic; *Consultant:* Spectranetics

Ted Bass: Nothing to Disclose

Emmanouil Brilakis: *Consultant/Speaker:* Abbott Vascular, Asahi, Boston Scientific, Elsevier, GE Healthcare, Somahlution, St. Jude Medical, Terumo; *Research:* Boston Scientific, InfraRedx; *Spouse:* employee of Medtronic

Douglas Drachman: Nothing to Disclose

Luis Guzman: Nothing to Disclose

Ethisham Mahmud: *Advisory Board:* Corindus, Medtronic; *Consultant/Research:* Corindus; *Speakers' Bureau:* Abbot Vascular; *Stock/Shareholder:* Abiomed

Kreton Mavromatis: *Consultant:* Direct Flow; *Speaker:* Bard

Sahil Parikh: Nothing to Disclose

Michael Ragosta: *Consultant/Research:* Corindus

Sunil Rao: *Advisory Board/Consultant:* Medtronic, Terumo Interventional Systems Inc.; *Speakers' Bureau:* Medtronic

Kalyani Trivedi: Nothing to Disclose

Bonnie Weiner: *Consultant:* Cytosorbents, Mesoblast, SentreHeart, Soundbite Medical Solutions, WhiteSwell; *Research:* Stryker Neurovascular; *Stock/Shareholder:* Imaging Core Lab Services

SCAI: Anne Marie Smith, MBA; Nerissa Legge: Nothing to disclose

Rockpointe: Barry Watkins, PhD; Blair St. Amand; Mary Stanley; Jay Katz, CHCP: Nothing to disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

GLOSSARIES

First-generation Drug-Eluting Stents							
	Drug Eluted from Stent	Polymer Material	Polymer Type	Polymer Distribution	Polymer Thickness	Platform Material	Stent Strut Thickness
Cypher	Sirolimus	PEVA/ PBMA	Durable	Circumferential	13 µm	Stainless Steel	140 µm
TAXUS Express, Liberte	Paclitaxel	SIBS	Durable	Circumferential	22 µm	Stainless Steel	132 µm
TAXUS ELEMENT	Paclitaxel	SIBS	Durable	Circumferential	8 µm	Platinum-chromium	81 µm

Second-generation Drug-Eluting Stents							
	Drug Eluted from Stent	Polymer Material	Polymer Type	Polymer Distribution	Platform Material	Stent Strut Thickness	
Xience Family	Everolimus	PBMA/ PVDF-HFP	Durable	Circumferential	CoCr	81 µm	
Xience Promus	Everolimus	PBMA/ PVDH-HFP	Durable	Circumferential	CoCr; PICr	81 µm	
Endeavor	Zotarolimus	PMC/LMA/HPMA/ 3-MPMA	Durable	Circumferential	CoCr	91 µm	
Resolute	Zotarolimus	PBMA/PHMA/ PVP/PVA	Durable	Circumferential	CoCr	91 µm	
BioMatrix Nobori	Biolimus	PDLLA	Biodegradable	Abluminal	SS	120 µm	
Yukon PC	Sirolimus	PDLLA	Biodegradable	Circumferential	SS	87 µm	
Synergy	Everolimus	PLGA	Biodegradable	Abluminal	PICr	74 µm	
Orsiro	Sirolimus	PLLA	Biodegradable	Circumferential	CoCr	60 µm	

Palmerini T et al. *J Am Coll Cardiol*. 2013;62:1915-1921.

Stefanini GG et al. *Heart*. 2014;100:1051-1061.

STEERING COMMITTEE



CINDY GRINES, MD, FACC, FSCAI

Vice President, Quality and Academic Affairs
DMC Heart Hospital
Professor, Wayne State School of Medicine
Detroit, MI

Cindy Grines, MD, FACC, FSCAI has a long history of research, publications, and designing clinical trials. In addition, she has served as a Cath Lab Director for 15 years, as well as Program Director for the Interventional Cardiology Fellowship Program. She currently holds the position of Vice President of Quality and Academic Affairs at the Detroit Medical Center (DMC) Heart Hospital and serves as a Professor of Medicine at Wayne State University in Detroit.

Dr. Grines serves on the editorial boards of many leading journals, and has co-edited several medical handbooks, as well as serving as the editor of the *Journal of Interventional Cardiology*. She has authored more than 400 publications, numerous book chapters, and hundreds of medical journal articles regarding cardiac catheterization, percutaneous coronary intervention (PCI), acute myocardial infarction, gene therapy, and heart disease in women. Despite her academic credentials, she remains very active clinically and maintains a practical perspective to research studies.

STEERING COMMITTEE



JAMES B. HERMILLER, MD, FACC, FSCAI

Director, Interventional Cardiology Fellowship
Director, Interventional Cardiology
St. Vincent Medical Group
Indianapolis, IN

James B. Hermiller, MD, FACC, FSCAI graduated summa cum laude from both Miami University in Oxford, OH (undergraduate degree) and from the Ohio State School of Medicine, in Columbus, OH (medical degree). He completed an internal medicine internship and residency at the National Naval Medical Center in Bethesda, MD, where he was also Chief Resident. He completed his cardiology fellowship at Duke University Medical Center in Durham, NC.

Dr. Hermiller joined St. Vincent Medical Group in 1992. He serves as Director of Interventional Cardiology for St. Vincent Medical Group at St. Vincent Hospital in Indianapolis, IN and serves as Director of the Interventional Cardiology Fellowship Program at St. Vincent.